Ambitious Tevogen makes expansion announcement

Specialty immunotherapy company Tevogen Bio Holdings (Nasdaq: TVGN) has announced the execution of a lease agreement to expand its corporate headquarters (pictured above) in Warren, New Jersey, more than doubling its footprint.

This expanded space will centralize cross-functional teams, including executive leadership, regulatory affairs, corporate strategy and research and development - previously located in Philadelphia - with the promise of increasing operational efficiency and enhancing cross-team collaboration.

The headquarters will also house the company’s AI and generics and biosimilars initiatives, with dedicated facilities for Tevogen.AI’s growing team of data scientists and engineers as development of its proprietary AdapTcell and PredicTcell algorithms accelerates.